GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sinovac Biotech (SVA) shares

Learn how to easily invest in Sinovac Biotech shares.

Sinovac Biotech Ltd is a biotechnology business based in the US. Sinovac Biotech shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars. Sinovac Biotech employs 1,959 staff and has a trailing 12-month revenue of around USD$510.6 million.

How to buy shares in Sinovac Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

Is it a good time to buy Sinovac Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sinovac Biotech shares at a glance

Information last updated 2021-10-16.
Latest market close$6.47
52-week range$6.47 - $6.47
50-day moving average $6.47
200-day moving average $6.47
Wall St. target price$6.00
PE ratio 6.6632
Dividend yield N/A (0%)
Earnings per share (TTM) $0.97

Sinovac Biotech stock price (NASDAQ: SVA)

Use our graph to track the performance of SVA stocks over time.

Sinovac Biotech price performance over time

Historical closes compared with the close of $6.47 from 2021-10-18

1 week (2021-10-12) 6.47
1 month (2021-09-17) 6.47
3 months (2021-07-19) 6.47
6 months (2021-04-19) 6.47
1 year (2020-10-15) N/A
2 years (2019-10-15) N/A
3 years (2018-10-19) 7.51
5 years (2016-10-19) 9.29%

Is Sinovac Biotech under- or over-valued?

Valuing Sinovac Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sinovac Biotech's P/E ratio

Sinovac Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Sinovac Biotech shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sinovac Biotech's EBITDA

Sinovac Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $219.5 million.

The EBITDA is a measure of a Sinovac Biotech's overall financial performance and is widely used to measure a its profitability.

Sinovac Biotech financials

Revenue TTM $510.6 million
Operating margin TTM 42.26%
Gross profit TTM $443.4 million
Return on assets TTM 11.46%
Return on equity TTM 25.16%
Profit margin 21.61%
Book value $7.52
Market capitalisation $642.4 million

TTM: trailing 12 months

Shorting Sinovac Biotech shares

There are currently 188,500 Sinovac Biotech shares held short by investors – that's known as Sinovac Biotech's "short interest". This figure is 0% down from 188,500 last month.

There are a few different ways that this level of interest in shorting Sinovac Biotech shares can be evaluated.

Sinovac Biotech's "short interest ratio" (SIR)

Sinovac Biotech's "short interest ratio" (SIR) is the quantity of Sinovac Biotech shares currently shorted divided by the average quantity of Sinovac Biotech shares traded daily (recently around inf billion). Sinovac Biotech's SIR currently stands at 0. In other words for every 100,000 Sinovac Biotech shares traded daily on the market, roughly 0 shares are currently held short.

However Sinovac Biotech's short interest can also be evaluated against the total number of Sinovac Biotech shares, or, against the total number of tradable Sinovac Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sinovac Biotech's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sinovac Biotech shares in existence, roughly 0 shares are currently held short) or 0.0032% of the tradable shares (for every 100,000 tradable Sinovac Biotech shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sinovac Biotech.

Sinovac Biotech share dividends

We're not expecting Sinovac Biotech to pay a dividend over the next 12 months.

Sinovac Biotech share price volatility

Over the last 12 months, Sinovac Biotech's shares have ranged in value from as little as $6.47 up to $6.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sinovac Biotech's is 0.0529. This would suggest that Sinovac Biotech's shares are less volatile than average (for this exchange).

Sinovac Biotech overview

Sinovac Biotech Ltd. , a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu. 1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site